HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Mylan Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Mylan Intelligence Report

Generated from 22 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 75%

Evidence

128 items

Sources

20

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Mylan maintains an active intelligence profile across Immunology, Immunosuppressant, Anesthesia, Neuromuscular Blockade, Oncology. 22 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 75% across 3 tracked sources. Highest-priority development: FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan Labs Ltd..

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — SUGAMMADEX SODIUM (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 2169 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE MOFETIL HYDROCHLORIDE (SUPPL)

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SUGAMMADEX SODIUM (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — FERRIC CARBOXYMALTOSE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — FERRIC CARBOXYMALTOSE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approval for Acetazolamide Sodium by Mylan

    Neurology · Carbonic Anhydrase Inhibitor

  • FDA Grants Approval for Pomalidomide Supplement by Mylan

    Oncology · Small Molecule

  • FDA Grants Approval for Ferric Carboxymaltose by Mylan Labs

    Hematology · Iron Deficiency Anemia

  • FDA Approves Ferric Carboxymaltose for Mylan's ANDA217076

    Hematology · Iron Deficiency Anemia

  • FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs

    Hematology · Iron Deficiency Anemia

  • FDA Grants Approval for Mylan's Liraglutide ANDA213155

    Endocrinology · GLP-1 Agonist

  • FDA Grants Approval for Ferric Carboxymaltose by Mylan

    Hematology · Iron Deficiency Anemia

  • Mylan's Methotrexate Sodium ANDA081235 Receives Abbreviated Approval

    Oncology · Chemotherapy

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.